Replimune

Replimune

Yahoo Finance • 5 days ago

Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.19%.  September E-mini S&P futures (ESU26) fell -0.34%, and... Full story

Yahoo Finance • 28 days ago

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2... Full story

Yahoo Finance • 29 days ago

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival... Full story

Yahoo Finance • last month

REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or “the Company”) (N... Full story

Yahoo Finance • last month

Replimune surges day after FDA Commissioner Makary resigns

[Business graph, chart green background.Copy space] design master * Replimune (REPL [https://seekingalpha.com/symbol/REPL]), which has been critical of the FDA over its application for a melanoma treatment, is up ~30% Wednesday, the day... Full story

Yahoo Finance • last month

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Quantum Cyber (NASDAQ:QUCY) shares rose 163.0% to $0.85 during Wednesday's regular session. The market value of their outstanding shares is at $4.0 million. Whitehawk Therapeutics (NASDAQ:WHWK) stock moved upwards by 29.59% to $5.... Full story

Yahoo Finance • 2 months ago

Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech stocks to invest in. TheFly reported on April 13 that Jefferies cut its rating on REPL from Buy to Hold and reduce... Full story

Yahoo Finance • 2 months ago

Street sours on Replimune as stock hits all-time low on melanoma drug rejection

[Financial crisis down 3d red arrow economy business graph on money crash market background with bankruptcy decrease bad finance chart diagram or loss investment economic recession sales and low price.] Lemon_tm As shares of Replimune Gro... Full story

Yahoo Finance • 2 months ago

Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Replimune Group, Inc. (NASDAQ: REPL). The investigation focuses on Replimune’s executive officers and whether... Full story

Yahoo Finance • 2 months ago

Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1

[Chemist developing new medicine in laboratory] Luis Alvarez * Replimune shares tumbled 56% in premarket trading on Monday after the FDA on Friday declined [https://seekingalpha.com/news/4574207-replimune-sees-layoffs-fda-snubs-cancer-d... Full story

Yahoo Finance • 3 months ago

FDA Review Looms As Replimune Faces Weak Technical Setup

Replimune Group shares are down on Thursday. The company faces an upcoming FDA review decision on Friday, 10 April. Replimmune RP1 Filing Faces Regulatory Hurdles In October 2025, the U.S. Food and Drug Administration (FDA) accepted the... Full story

Yahoo Finance • 3 months ago

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a com... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Lower Friday Afternoon

Health care stocks declined Friday afternoon, with the NYSE Health Care Index decreasing 0.7% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz

[Wall street and Broadway road sign in New York City] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. SUN... Full story

Yahoo Finance • 4 months ago

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story

Yahoo Finance • 5 months ago

Replimune Group GAAP EPS of -$0.77 beats by $0.01

* Replimune Group press release [https://seekingalpha.com/pr/20385487-replimune-reports-fiscal-third-quarter-2026-financial-results-and-provides-corporate-update] (REPL [https://seekingalpha.com/symbol/REPL]): Q3 GAAP EPS of -$0.77 beats... Full story

Yahoo Finance • 8 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data and updated... Full story

Yahoo Finance • 8 months ago

Trending tickers: HSBC, Cleveland-Cliffs, GSI Technology, Beyond Meat and Replimune

Cleveland-Cliffs (CLF) Shares in Cleveland-Cliffs were lower in pre-market trading after closing 21% higher on Monday as the US steelmaker said it would increase efforts to develop its rare earth minerals business, an increasingly strateg... Full story

Yahoo Finance • 8 months ago

Noteworthy Monday Option Activity: UNH, REPL, CELC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has been traded thus far today, a contract... Full story